CLDX

Celldex Therapeutics (CLDX) is the lead sponsor of 8 active clinical trials listed on ClinicalTrials.gov^[4], including 4 Phase 3^[1], 2 Phase 2^[2], 2 Phase 1^[3].

Trial NCT07256392^[5] evaluates barzolvolimab in Chronic Spontaneous Urticaria with a target enrollment of 1370 participants. Trial NCT06445023^[6] evaluates barzolvolimab in Chronic Spontaneous Urticaria with a target enrollment of 963 participants. Trial NCT06455202^[7] evaluates barzolvolimab in Chronic Spontaneous Urticaria with a target enrollment of 976 participants.

No Form 4 insider filings for CLDX were recorded at the SEC in the past 30 days^[8].